NASDAQ
HKPD
Last Price
US $0.46
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Cellyan Biotechnology Co., Ltd cash flow to debt ratio of 23.97% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Cellyan Biotechnology Co., Ltd's free cash flow has increased -185.88% from $-482.35K last year to $414.23K, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Cellyan Biotechnology Co., Ltd's debt to equity ratio is 0.44, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Cellyan Biotechnology Co., Ltd's debt has decreased relative to shareholder equity from 0.49 last year to 0.44 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Cellyan Biotechnology Co., Ltd has a net debt to EBITDA ratio of 1.35x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial risk - ICR.
Cellyan Biotechnology Co., Ltd's interest coverage ratio is -13.84, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Cellyan Biotechnology Co., Ltd's profit margin has decreased (-153.84%) in the last year from 7.97% to -4.29%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Cellyan Biotechnology Co., Ltd's short-term assets of $8.73M exceed its short-term liabilities of $2.92M
Decreasing performance - ROA.
Cellyan Biotechnology Co., Ltd's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Cellyan Biotechnology Co., Ltd's return on equity of -13.85%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Cellyan Biotechnology Co., Ltd's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Cellyan Biotechnology Co., Ltd had positive net income in only 2.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
Cellyan Biotechnology Co., Ltd has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Cellyan Biotechnology Co., Ltd has a free cash flow yield of 8.28%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
Cellyan Biotechnology Co., Ltd's yearly earnings has decreased -102.03% since last year from $1.33M to $-27.06K, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Cellyan Biotechnology Co., Ltd's yearly revenue has increased 21.72% since last year from $16.69M to $20.31M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -8.91% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Cellyan Biotechnology Co., Ltd has insufficient revenue history to calculate 3-year revenue CAGR.
Decreasing performance - Revenue consistency.
Cellyan Biotechnology Co., Ltd had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Cellyan Biotechnology Co., Ltd had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Cellyan Biotechnology Co., Ltd has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Cellyan Biotechnology Co., Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Cellyan Biotechnology Co., Ltd is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Cellyan Biotechnology Co., Ltd has an EV/EBITDA ratio of 5.49x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Cellyan Biotechnology Co., Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Cellyan Biotechnology Co., Ltd has a price-to-book ratio of 0.97x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Cellyan Biotechnology Co., Ltd has a price-to-sales ratio of 0.31x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-13.85%
Return on equity
ROIC: -8.91%
Valuation History
-6.6X
Price to Earnings
EV/EBITDA: -13.1X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $0.46
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.